November 9, 2021 06:59 AM ESTUpdated 02:13 PM

Looking to get ahead in a packed migraine market, Amgen touts head-to-head data for Aimovig

Nicole DeFeudis

Editor

A year after Amgen announced its injectable migraine prevention drug Aimovig proved a better option than the widely used treatment topiramate in a head …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Looking to get ahead in a packed migraine market, Amgen touts head-to-head data for Aimovig

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Look­ing to get ahead in a packed mi­graine mar­ket, Am­gen touts head-to-head da­ta for Aimovig

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Looking to get ahead in a packed migraine market, Amgen touts head-to-head data for Aimovig

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role